HRS-6209 clinical trials
Also written HRS-6209.
How each study uses HRS-6209 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the HRS-6209 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HRS-6209
- 3
Studies by the year they started
8 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 1
Jiangsu HengRui Medicine Co., Ltd. (5) · Atridia Pty Ltd. (1) · Fudan University (1) · Shandong Suncadia Medicine Co., Ltd. (1)
Often tested with
Tested in the same studies.
HRS-4508 (2) · HRS-9813 (1) · Dalpiciclib (1) · Pyrotinib (1) · Trastuzumab rezetecan (1) · Adebrelimab (1) · Camrelizumab (1) · Tizetatug rezetecan (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test HRS-6209.
- Dec 2026A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast CancerPhase 1/2 · Jiangsu HengRui Medicine Co., Ltd.
- Dec 2026A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid TumorsPhase 1 · Jiangsu HengRui Medicine Co., Ltd.
- Apr 2027A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative CancerPhase 1 · Atridia Pty Ltd.
Studies
Open first, then newest update. How each study uses HRS-6209 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast CancerNot yet recruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT07894328Written as HRS-6209 + Letrozole
- A Trial of HRS-6209 in Combination With Other Antitumor Therapies in Breast Cancer Patients or HRS-9813 as Monotherapy in Patients With Advanced Solid TumorsRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06555068Written as HRS-6209 in Combination with Fulvestrant
- A Trial of HRS-6209-205 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Combination Therapy in Subjects With HR-Positive/HER2-Negative CancerRecruitingPhase 1Atridia Pty Ltd.NCT07358377Written as HRS-6209 Capsules and fulvestrant injection
- A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast CancerRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06974929Written as HRS-6209 Capsules
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as HRS-6209
- A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer PatientsRecruitingPhase 1/2Shandong Suncadia Medicine Co., Ltd.NCT06679036Written as HRS-6209
- A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy ParticipantsActive, not recruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT07610148Written as HRS-6209 Capsule (old formulation)
- A Phase I Clinical Study of the Safety, Tolerability,Pharmacokinetics, and Initial Efficacy of HRS-6209 Monotherapy in Patients With Advanced Solid TumorsActive, not recruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05781048Written as HRS-6209
Given beside what is tested · 1 — HRS-6209 is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 18, 2026.